Polinosis en la provincia de Lleida

Antecedentes y objetivos: Se realizó un estudio transversal para determinar qué pólenes producían sensibilización con más frecuencia en la provincia de Lleida. Material y métodos: La población a estudio incluyó a pacientes que acudieron por primera vez a la consulta de alergia por síntomas respiratorios entre marzo de 2001 y marzo de 2002, y que presentaron alguna positividad en las pruebas cutáneas. Se recogieron datos sobre la edad, el sexo, la filiación, la profesión, los síntomas y las sensibilizaciones encontradas en las pruebas cutáneas. Esta información se analizó con el programa SPSS junto al departamento de investigación biomédica de Lleida. Se incluyeron 424 pacientes (45,75% varones y 54,25% mujeres). El promedio de edad fue de 28 años. El 60,14% de los pacientes procedía de la comarca del Segriá donde se encuentra la capital. Resultados: Un 79,72% de los pacientes estaba sensibilizado a pólenes; los más frecuentes fueron los de gramíneas (57,08%) seguidos de las chenopodiáceas (49,29%) y el olivo (34,67%). Encontramos un 4,48% de los pacientes monosensibilizados a las chenopodiáceas. Conclusiones: La presencia de suelos salinos junto a una escasa pluviosidad en Lleida favorece el crecimiento de las chenopodiáceas, por lo que no es de extrañar la prevalencia alta de sensibilización a dicho polen encontrada en este estudio, con un considerable porcentaje de monosensibilizados. Este estudio es el primero que recoge datos sobre la sensibilización a aeroalergenos en la provincia de Lleida

Insect Venom Immunotherapy: Analysis of the Safety and Tolerance of 3 Buildup Protocols Frequently Used in Spain

Introduction: Hymenoptera venom immunotherapy (VIT) is an effective treatment but not one devoid of risk, as both local and systemic adverse reactions may occur, especially in the initial phases. We compared the tolerance to 3 VIT buildup protocols and analyzed risk factors associated with adverse reactions during this phase. Materials and Methods: We enrolled 165 patients divided into 3 groups based on the buildup protocol used (3, 4, and 9 weeks). The severity of systemic reactions was evaluated according to the World Allergy Organization model. Results were analyzed using exploratory descriptive statistics, and variables were compared using analysis of variance. Results: Adverse reactions were recorded in 53 patients (32%) (43 local and 10 systemic). Local reactions were immediate in 27 patients (63%) and delayed in 16 (37%). The severity of the local reaction was slight/moderate in 15 patients and severe in 13. Systemic reactions were grade 1-2. No significant association was found between the treatment modality and the onset of local or systemic adverse reactions or the type of local reaction. We only found a statistically significant association between severity of the local reaction and female gender. As for the risk factors associated with systemic reactions during the buildup phase, we found no significant differences in values depending on the protocol used or the insect responsible. Conclusions: The buildup protocols compared proved to be safe and did not differ significantly from one another. In the population studied, patients undergoing the 9-week schedule presented no systemic reactions. Therefore, this protocol can be considered the safest approach

Key Issues in Hymenoptera Venom Allergy: An Update.

In this review, the Hymenoptera Allergy Committee of the SEAIC analyzes the most recent scientific literature addressing problems related to the diagnosis of hymenoptera allergy and to management of venom immunotherapy. Molecular diagnosis and molecular risk profiles are the key areas addressed. The appearance of new species of hymenoptera that are potentially allergenic in Spain and the associated diagnostic and therapeutic problems are also described. Finally, we analyze the issue of mast cell activation syndrome closely related to hymenoptera allergy, which has become a new diagnostic challenge for allergists given its high prevalence in patients with venom anaphylaxis

Insect Venom Immunotherapy: Analysis of the Safety and Tolerance of 3 Buildup Protocols Frequently Used in Spain

Introduction: Hymenoptera venom immunotherapy (VIT) is an effective treatment but not one devoid of risk, as both local and systemic adverse reactions may occur, especially in the initial phases. We compared the tolerance to 3 VIT buildup protocols and analyzed risk factors associated with adverse reactions during this phase.Materials and Methods: We enrolled 165 patients divided into 3 groups based on the buildup protocol used (3, 4, and 9 weeks). The severity of systemic reactions was evaluated according to the World Allergy Organization model.Results were analyzed using exploratory descriptive statistics, and variables were compared using analysis of variance. Results: Adverse reactions were recorded in 53 patients (32%) (43 local and 10 systemic). Local reactions were immediate in 27 patients (63%) and delayed in 16 (37%). The severity of the local reaction was slight/moderate in 15 patients and severe in 13. Systemic reactions were grade 1-2. No significant association was found between the treatment modality and the onset of local or systemic adverse reactions or the type of local reaction. We only found a statistically significant association between severity of the local reaction and female gender. As for the risk factors associated with systemic reactions during the buildup phase, we found no significant differences in values depending on the protocol used or the insect responsible.Conclusions: The buildup protocols compared proved to be safe and did not differ significantly from one another. In the population studied, patients undergoing the 9-week schedule presented no systemic reactions. Therefore, this protocol can be considered the safest approach

No effect of antihypertensive drugs on severity of anaphylaxis and side-effects during venom immunotherapy

Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) -- JUN 01-05, 2019 -- Lisbon, PORTUGALWOS: 000480254002001European Acad Allergy & Clin Immuno